Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 195

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial

Open access
Hall, Peter S., Swinson, Daniel, Cairns, David A., Waters, Justin S., Petty, Russell, Allmark, Christine, Ruddock, Sharon, Falk, Stephen, Wadsley, Jonathan, Roy, Rajarshi, Tillett, Tania, Nicoll, Jonathan, Cummins, Sebastian, Mano, Joseph, Grumett, Simon, Stokes, Zuzana, Kamposioras, Konstantinos-Velios, Chatterjee, Anirban, Garcia, Angel, Waddell, Tom, Guptal, Kamalnayan, Maisey, Nick, Khan, Mohammed, Dent, Jo, Lord, Simon, Crossley, Ann, Katona, Eszter, Marshall, Helen, Grabsch, Heike I., Velikova, Galina, Ow, Pei Loo, Handforth, Catherine, Howard, Helen, Seymour, Matthew T., GO2 Trial Investigators, James, Eleanor, Cheeseman, Sue, Roques, Tom, Reed, Nick, Candish, Charles, Fyfe, David, Last, Kim, Ellis, Richard, Samuel, Lesley, Herbertson, Rebecca, Medley, Louise, Patel, Kinnari, Sherriff, David, Robinson, Angus, Bezecny, Pavel, Wilkins, Dunca, McGeoch, Adam, Propper, Daniel, Williams, Olwyn, Hilman, Serena, Raouf, Sherif, Hobbs, Claire, Parkinson, Jo, Wadd, Nick, Saku, W, Kunene, Victori, Askill, Colin, Jamil, Arshad, Cattell, Emma, Gorf, Lauren, Vigneswaran, Vallipuram, Beaumont, Erica, Zubair, Syed, Jones, Elin, Reed, Nicholas, Shablak, Alaaeldin, Bozas, George, Rao, Sheela, Bennet, Michael, Askey, Joanne, Griffiths, Gareth, Clive, Sally, Potter, Vanessa, Gall, Jean, Twelves, Chris, Sydes, Matt, Valle, Juan, Webster, Jo, Jones, Marc, Collinson, Fiona, Brown, Julia, Brook, Louise·2021·JAMA Oncology

Abstract

Importance: Older and/or frail patients are underrepresented in landmark cancer trials. Tailored research is needed to address this evidence gap. Objective: The GO2 randomized clinical trial sought to optimize chemotherapy dosing in older and/or frail patients with advanced gastroesophageal cancer, and explored baseline geriatric assessment (GA) as a tool for treatment decision-making. Design, Setting, and Participants: This multicenter, noninferiority, open-label randomized trial took place at oncology clinics in the United Kingdom with nurse-led geriatric health assessment. Patients were recruited for whom full-dose combination chemotherapy was considered unsuitable because of advanced age and/or frailty. Interventions: There were 2 randomizations that were performed: CHEMO-INTENSITY compared oxaliplatin/capecitabine at Level A (oxaliplatin 130 mg/m2 on day 1, capecitabine 625 mg/m2 twice daily on days 1-21, on a 21-day cycle), Level B (doses 0.8 times A), or Level C (doses 0.6 times A). Alternatively, if the patient and clinician agreed the indication for chemotherapy was uncertain, the patient could instead enter CHEMO-BSC, comparing Level C vs best supportive care. Main Outcomes and Measures: First, broad noninferiority of the lower doses vs reference (Level A) was assessed using a permissive boundary of 34 days reduction in progression-free survival (PFS) (hazard ratio, HR = 1.34), selected as acceptable by a forum of patients and clinicians. Then, the patient experience was compared using Overall Treatment Utility (OTU), which combines efficacy, toxic effects, quality of life, and patient value/acceptability. For CHEMO-BSC, the main outcome measure was overall survival. Results: A total of 514 patients entered CHEMO-INTENSITY, of whom 385 (75%) were men and 299 (58%) were severely frail, with median age 76 years. Noninferior PFS was confirmed for Levels B vs A (HR = 1.09 [95% CI, 0.89-1.32]) and C vs A (HR = 1.10 [95% CI, 0.90-1.33]). Level C produced less toxic effects and better OTU than A or B. No subgroup benefited from higher doses: Level C produced better OTU even in younger or less frail patients. A total of 45 patients entered the CHEMO-BSC randomization: overall survival was nonsignificantly longer with chemotherapy: median 6.1 vs 3.0 months (HR = 0.69 [95% CI, 0.32-1.48], P = .34). In multivariate analysis in 522 patients with all variables available, baseline frailty, quality of life, and neutrophil to lymphocyte ratio were independently associated with OTU, and can be combined in a model to estimate the probability of different outcomes. Conclusions and Relevance: This phase 3 randomized clinical trial found that reduced-intensity chemotherapy provided a better patient experience without significantly compromising cancer control and should be considered for older and/or frail patients. Baseline geriatric assessment can help predict the utility of chemotherapy but did not identify a group benefiting from higher-dose treatment. Trial Registration: isrctn.org Identifier: ISRCTN44687907.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2021.0848

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 195

Metadata

Authors
Hall, P. S., Swinson, D., Cairns, D. A., Waters, J. S., Petty, R., Allmark, C., Ruddock, S., Falk, S., Wadsley, J., Roy, R., Tillett, T., Nicoll, J., Cummins, S., Mano, J., Grumett, S., Stokes, Z., Kamposioras, K.-V., Chatterjee, A., Garcia, A., Waddell, T., Guptal, K., Maisey, N., Khan, M., Dent, J., Lord, S., Crossley, A., Katona, E., Marshall, H., Grabsch, H. I., Velikova, G., Ow, P. L., Handforth, C., Howard, H., Seymour, M. T., GO2 Trial Investigators, James, E., Cheeseman, S., Roques, T., Reed, N., Candish, C., Fyfe, D., Last, K., Ellis, R., Samuel, L., Herbertson, R., Medley, L., Patel, K., Sherriff, D., Robinson, A., Bezecny, P., Wilkins, D., McGeoch, A., Propper, D., Williams, O., Hilman, S., Raouf, S., Hobbs, C., Parkinson, J., Wadd, N., Saku, W., Kunene, V., Askill, C., Jamil, A., Cattell, E., Gorf, L., Vigneswaran, V., Beaumont, E., Zubair, S., Jones, E., Reed, N., Shablak, A., Bozas, G., Rao, S., Bennet, M., Askey, J., Griffiths, G., Clive, S., Potter, V., Gall, J., Twelves, C., Sydes, M., Valle, J., Webster, J., Jones, M., Collinson, F., Brown, J., & Brook, L.
Venue
JAMA Oncology
Published
2021-06-01
Volume
7
Issue
6
Pages
869
ISSN
2374-2437 (ISSN-L)
OpenAlex
W3161258718
Cited by
195
References
7
FWCI
15.17
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamaoncol.2021.0848
The paper
Hall, P. S., Swinson, D., Cairns, D. A., Waters, J. S., Petty, R., Allmark, C., Ruddock, S., Falk, S., Wadsley, J., Roy, R., Tillett, T., Nicoll, J., Cummins, S., Mano, J., Grumett, S., Stokes, Z., Kamposioras, K.-V., Chatterjee, A., Garcia, A., . . . Brook, L. (2021). Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2021.0848

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.